COVID -19 vaccine hesitancy and determinants in Ethiopia: A national pilot survey.

COVID-19 Ethiopia Vaccine hesitancy mobile phone

Journal

Ethiopian medical journal
ISSN: 0014-1755
Titre abrégé: Ethiop Med J
Pays: Ethiopia
ID NLM: 0373223

Informations de publication

Date de publication:
30 Oct 2022
Historique:
medline: 30 10 2022
pubmed: 30 10 2022
entrez: 29 1 2024
Statut: ppublish

Résumé

Despite major advances in Corona Virus Disease 2019 (COVID-19) vaccine development, vaccine hesitancy threatens the progress made to curb the disease. We aimed to assess the level of COVID-19 vaccine hesitancy and the underlying determinants in Ethiopia. A pilot mobile phone survey of adults in Ethiopia with mobile phones selected randomly. The pilot survey included 614 participants who were predominantly male (71.7%), and married (68.2%) with a median age of 34 years (interquartile range [IQR] = 14.0). Overall, 150 (24.4%) participants reported to have been vaccinated; either the first [57 (38%)], second [19 (12.7%)], or both [74 (49.3%)] doses. About one in six participants (16.3%; n=100) reported vaccine hesitancy, with a significant difference by employment status, with self-employed more likely to show hesitancy [adjusted odds ratio (AOR) 1.85, 95% CI (1.05-3.27)], and region. Major drivers of hesitancy were lack of interest [n=30 (30%)], fear of side-effects [n=24 (24%)], and lack of trust in the vaccine [n=13 (13%)]. Having chronic disease conditions in the family had no association with hesitancy (p > 0.05). While representativeness of the sample is an issue, the findings show a relatively low rate of COVID-19 vaccine hesitancy among the Ethiopian population. The major drivers of hesitancy, lack of interest, fear of side-effects, and lack of trust in the vaccine, may be reversed by disseminating accurate and timely information using credible sources across communities.

Identifiants

pubmed: 38283904
pmc: PMC10812837

Types de publication

Journal Article

Langues

eng

Pagination

40-47

Auteurs

Sewit Timothewos (S)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Hanna Negussie (H)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Bethelhem Fekadu (B)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Winini Belay (W)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Eyerusalem Getachew (E)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Medhin Selamu (M)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.
Addis Ababa University, WHO Collaborating Center for Mental Health Research and Capacity Building, Department of Psychiatry, College of Health sciences, Addis Ababa, Ethiopia.

Abigiya Wondimagegnehu (A)

Addis Ababa University, College of Health Sciences, School of Public Health, Addis Ababa, Ethiopia.
Martin-Luther-University, Institute of Medical Epidemiology, Bio statistics and Informatics, Halle, Germany.

Tigist Eshetu (T)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Tigest Ajeme (T)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Charlotte Hanlon (C)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.
Addis Ababa University, WHO Collaborating Center for Mental Health Research and Capacity Building, Department of Psychiatry, College of Health sciences, Addis Ababa, Ethiopia.
King's College London, Institute of Psychiatry, Psychology and Neuroscience, Centre for Global Mental Health, London, UK.

Yimtubezinash Woldeamanuel (Y)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.
Addis Ababa University, College of Health Sciences, Department of Microbiology, Parasitology, Immunology and Pathology, Addis Ababa, Ethiopia.

Tsegahun Manyazewal (T)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.

Abebaw Fekadu (A)

Addis Ababa University, Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia.
Addis Ababa University, WHO Collaborating Center for Mental Health Research and Capacity Building, Department of Psychiatry, College of Health sciences, Addis Ababa, Ethiopia.
Brighton and Sussex Medical School, Global Health and Infection Department, Brighton, UK.

Classifications MeSH